Search

Displaying results 9491 - 9500 of 9726 in total
  1. Drug

    Zelenirstat

    go.drugbank.com/drugs/DB15567
    Investigational

    Zelenirstat (PCLX-001) is a first-in-kind N-Myristoyltransferase (NMT) inhibitor being developed by [Pacylex Pharmaceuticals](https://pacylex.com).

  2. Drug

    Adagrasib

    go.drugbank.com/drugs/DB15568
    ApprovedInvestigational

    [A254052] In a phase I/IB clinical study that included patients with KRAS<sup>G12C</sup>-mutated advanced solid tumors (NCT03785249), adagrasib exhibited anti-tumor activity. … [A254052,A254057,A254946] In February 2022, the FDA accepted a new drug application (NDA) for adagrasib for the treatment of patients with previously treated KRAS<sup>G12C</sup>–positive NSCLC.

  3. Drug

    Zilucoplan

    go.drugbank.com/drugs/DB15636
    ApprovedInvestigational

    Zilucoplan is a 15 amino-acid, synthetic macrocyclic peptide. … It is a complement inhibitor that works to prevent the activation of C5, which is a complement protein involved in the innate immune system to initiate inflammatory responses.

    Synonyms: N2-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-L-VALYL-L-TYROSYL-3-(1H-PYRROLO(2,3-B)PYRIDIN-3-YL)-L-ALANYL-L-.ALPHA., -HYDROXY-, 15-ETHER WITH N-ACETYL-L-LYSYL-L-VALYL-L-.ALPHA.-GLUTAMYL-L-ARGINYL-L-PHENYLALANYL-L-.ALPHA.-ASPARTYL-N-METHYL-L-.ALPHA.-ASPARTYL-3-METHYL-
  4. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    Zavegepant (BHV-3500) is a calcitonin gene-related peptide (CGRP) receptor antagonist. … [L45505] CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways.

  5. Drug

    Zetomipzomib

    go.drugbank.com/drugs/DB16070
    Investigational

    Zetomipzomib is under investigation in clinical trial NCT04033926 (A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis).

  6. Drug

    Eplontersen

    go.drugbank.com/drugs/DB16199
    ApprovedInvestigational

    It was previously investigated as a potential treatment for hereditary transthyretin-mediated amyloidosis. … [A262985] As eplontersen targets both the WT and mutant TTR, it poses tremendous promises as a treatment.

  7. Drug

    Leniolisib

    go.drugbank.com/drugs/DB16217
    ApprovedInvestigational

    Leniolisib is a potent and selective inhibitor of phosphoinositide 3-kinase δ (PI3Kδ). … [L45758] APDS is a primary immunodeficiency caused by mutations in genes encoding the PI3Kδ, thereby increasing the activity of PI3Kδ, causing immune dysfunction, and elevating susceptibility to infections

  8. Drug

    Polyinosinic-polycytidylic acid

    go.drugbank.com/drugs/DB16467
    Investigational

  9. Drug

    Ivarmacitinib

    go.drugbank.com/drugs/DB16756
    Investigational

    Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions.

  10. Drug

    Tebipenem pivoxil

    go.drugbank.com/drugs/DB16840
    Approved

    Tebipenem pivoxil is an orally administered prodrug of tebipenem, a carbapenem antibacterial that kills bacteria by binding essential penicillin-binding proteins and disrupting cell wall biosynthesis. … severe or resistant Gram-negative infections but had until now been available only intravenously, meaning patients with resistant complicated urinary tract infections generally required hospitalization, a